All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results | 2004-001674-80 | A Randomised, Open, Parallel Group, Multicentre Study to Examine the Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Combination with Clopidogrel and Aspirin in Patients unde... | 2006-10-04 | due-trials |
| Reported results | 2005-004989-17 | A PHASE III, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF AST-120 FOR PREVENTION OF CHRONIC KIDNEY DISEASE PROGRESSION IN PATIENTS WITH MODERATE TO SEVERE CHRONIC KIDNEY DISEASE | 2013-05-09 | due-trials |
| Reported results | 2005-004990-13 | A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 for Prevention of Chronic Kidney Disease Progression in Patients with Moderate to Severe Chronic Kidney Disease including Ass... | 2011-10-18 | due-trials |
| Not reported | 2005-005457-22 | A phase IIa, multi-centre, randomised, placebo-controlled, double-blind, parallel group study of TA-5538, in patients with overactive bladder | 2007-01-18 | due-trials |
| Reported results | 2006-003323-37 | A Phase III, Randomised, Double-blind, Multi-centre, Withdrawal Study comparing MCI-196 versus Placebo in Chronic Kidney Disease Stage V Subjects on Dialysis with Hyperphosphataemia (Incorporatin... | 2009-11-11 | due-trials |
| Reported results | 2006-003324-11 | A Phase III, Double-blind, Multi-centre, Randomised, Parallel Group Design, Placebo-controlled, Flexible Dose Study of MCI-196 in Combination with a Calcium-based Phosphate Binder in Chronic Kidney Di... | 2010-01-07 | due-trials |
| Reported results | 2006-003330-15 | A Phase III, Multicentre, Open Label, Flexible dose, Long term Safety Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis with Hyperphosphataemia (incorporating a Comparison with S... | 2010-08-06 | due-trials |
| Reported results | 2006-006535-53 | A Phase III, Multi-centre, Double-blind, Randomised, Placebo-controlled, Multiple Fixed-dose Study of MCI-196 versus Placebo in Chronic Kidney Disease Stage V Subjects on Dialysis with Hyperphosphatae... | 2009-11-12 | due-trials |
| Reported results | 2007-003364-21 | A Phase III, Multicentre, Double-blind, Double-Dummy, Randomised, Flexible-dose, Comparative Study of MCI-196 versus Simvastatin for the Treatment of Dyslipidaemia in Subjects with Chronic Kidney Dise... | 2010-03-20 | due-trials |
| Reported results | 2008-000730-42 | An open-label, multi-centre, clinical study to collect information on the clinical use of argatroban in patients with heparin induced thrombocytopenia (HIT) Type II who require parenteral antithrombot... | 2011-02-02 | due-trials |
| Reported results | 2008-003397-17 | A Phase IIa, multi-centre, randomised, double-blind, placebo controlled, clinical study investigating the safety, tolerability and pharmacokinetics of two different infusion doses over 72 hours of a n... | 2010-11-05 | due-trials |
| Reported results | 2008-008732-84 | A Phase IIb, double-blind, parallel group, multi-centre, dose-finding study to investigate the efficacy and safety of 4 doses of MP-513 when added to ongoing metformin monotherapy in subjects with Typ... | 2011-04-14 | due-trials |
| Reported results | 2012-002470-31 | A phase II, multicentre, randomised, double-blind, parallel group, placebo-controlled, dose-finding study to evaluate the safety and efficacy of three different oral doses of MT-1303 administered for ... | 2014-10-23 | due-trials |
| Reported results | 2012-002480-98 | A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect on Urine Albumin-to-Creatinine Ratio (UACR), Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of Multiple Oral Do... | 2014-09-30 | due-trials |
| Reported results | 2012-002481-12 | A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect on Urine Albumin-to-Creatinine Ratio (UACR), Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of Multiple Oral Do... | 2014-09-15 | due-trials |
| Reported results | 2012-002581-12 | A Multi-centre, Randomised, Controlled, Parallel Group, Open-label Study Evaluating the Efficacy, Safety and Tolerability of Three Doses of Colestilan (MCI-196) Compared to Standard Therapy with a Cal... | 2015-01-26 | due-trials |
| Reported results | 2012-002582-35 | A Multi-centre, Open-label Study Evaluating the Safety and Tolerability of Colestilan (MCI-196) in Paediatric Subjects with Chronic Kidney Disease Stages 3b to 5 and with Hyperphosphataemia not on Dia... | 2014-12-17 | due-trials |
| Completed, but no date, and reported results Terminated | 2012-002583-27 | A Multi-centre, Flexible Dose, Parallel Group, Open-label, Active Control (Calcium-based Phosphate Binder), Long-term Extension Study Evaluating the Efficacy, Safety and Tolerability of Colestilan (MC... | bad-data | |
| Reported results | 2012-002639-27 | A phase II, multicentre study to evaluate the long-term safety and efficacy of MT-1303 in subjects with relapsing-remitting multiple sclerosis who have completed the MT-1303-E04 study Studio multic... | 2016-03-15 | due-trials |
| Reported results | 2012-005750-27 | A Phase IIa, Multicentre, Randomised, Double-Blind, Parallel Group, Placebo Controlled Study to Evaluate Safety, Tolerability and Clinical Efficacy of MT-1303 in Subjects with Moderate to Severe Chron... | 2014-11-21 | due-trials |
| Reported results | 2014-002556-77 | A Phase II, Multicentre, Randomised, Double-Blind, Parallel Group, Placebo Controlled Study to Evaluate Safety, Tolerability and Clinical Efficacy of MT 1303 in Subjects with Moderate to Severe Active... | 2016-10-10 | due-trials |
| Reported results | 2014-002557-19 | A Phase II, Open-label, Multicentre Study to Evaluate the Long-term Safety and Efficacy of MT-1303 in Subjects with Moderate to Severe Active Crohn’s Disease who have Completed the MT-1303-E13 Study | 2017-08-24 | due-trials |
| Reported results | 2016-002571-10 | A Phase IIa, Multi-Centre, Randomised, Double-Blind, Cross-Over, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of MT-8554 in Subjects with Painful Diabetic Peripheral Neurop... | 2018-08-08 | due-trials |
| Reported results | 2016-003521-42 | SAICoDis – Safety of Argatroban Infusion in Conduction Disturbances. A prospective, open, multicenter safety study to investigate conduction disturbances in patients receiving argatroban therapy. | 2021-05-12 | due-trials |
| Reported results | 2019-002108-41 | A Phase 3, Multi-center, Open-label, Safety Study of Oral Edaravone Administered over 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS) | 2021-10-07 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2019-004226-16 | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT 7117 in Adults and Adolescents with Erythropoietic Protoporphyria or X-L... | 2022-07-27 | bad-data |
| Reported results | 2019-004256-11 | A Phase 3b, Multicenter, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Oral Edaravone Administered for a Period of 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS) | 2023-09-29 | due-trials |
| Listed as ongoing, but also has a completion date | 2020-000134-17 | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects with Diffuse Cutaneous Systemic Scleros... | 2024-05-30 | bad-data |
| Reported results | 2020-000376-38 | A Phase 3, Multi-center, Open-label, Safety Extension Study of Oral Edaravone Administered over 96 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS) | 2023-08-09 | due-trials |
| Other | 2021-001831-17 | A Phase 3, Multicenter, Open-label, Long-term, Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects with Erythropoietic Protoporphyria (EPP) or X-Linked Prot... | not-yet-due | |
| Reported results Terminated | 2021-003900-42 | A Phase 3b, Multicenter, Randomized, Double-blind Extension Study to Evaluate the Continued Efficacy and Safety of Oral Edaravone Administered for an Additional Period of up to 48 Weeks Following Stud... | 2023-09-22 | due-trials |